^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CLDN1 inhibitor

    Related drugs:
    8ms
    Rescue of Nephrons With ALE.F02 (RENAL-F02) (clinicaltrials.gov)
    P2, N=80, Recruiting, Alentis Therapeutics AG | Active, not recruiting --> Recruiting | Trial completion date: Sep 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab)
    1year
    Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=21, Terminated, Alentis Therapeutics AG | N=160 --> 21 | Trial completion date: Feb 2028 --> Feb 2025 | Recruiting --> Terminated | Trial primary completion date: Feb 2028 --> Feb 2025; Reprioritization of Trial
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ALE.C04
    1year
    Rescue of Nephrons With ALE.F02 (RENAL-F02) (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Alentis Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab)
    1year
    FEGATO-01: A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis (clinicaltrials.gov)
    P1, N=41, Completed, Alentis Therapeutics AG | Recruiting --> Completed
    Trial completion • Metastases
    almost2years
    Rescue of Nephrons With ALE.F02 (RENAL-F02) (clinicaltrials.gov)
    P2, N=80, Recruiting, Alentis Therapeutics AG | N=60 --> 80
    Enrollment change
    |
    Rituxan (rituximab)
    almost2years
    FEGATO-01: A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis (clinicaltrials.gov)
    P1, N=38, Recruiting, Alentis Therapeutics AG | Phase classification: P1b --> P1 | N=28 --> 38 | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    2years
    Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer. (PubMed, Ther Adv Med Oncol)
    For the overall survival (OS) analysis, no statistically significant differences were observed between pembrolizumab [hazard ratios (HR) = 1.00, 95% CI: 0.94-1.07], sintilimab (HR = 0.99, 95% CI: 0.89-1.09), sugemalimab (HR = 0.98, 95% CI: 0.87-1.10), tislelizumab (HR = 0.97, 95% CI: 0.87-1.09), zolbetuximab (HR = 0.98, 95% CI: 0.91-1.07), and nivolumab (HR = 1.00). In addition, anti-claudin-18.2-targeted therapies presented similar OS (HR = 0.99, 95% CI: 0.95-1.04) and PFS (HR = 1.01, 95% CI: 0.91-1.12) compared to immunotherapy, although their toxicity profiles were distinct. Our network meta-analysis showed no significant difference in PFS, OS, or ORR between different checkpoint inhibitors or between immunotherapy and anti-claudin-18.2-targeted therapies in the first-line treatment of HER2-negative, unresectable, or metastatic gastric cancers.
    Retrospective data • Journal • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • Vyloy (zolbetuximab-clzb) • Cejemly (sugemalimab)
    2years
    Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Alentis Therapeutics AG
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ALE.C04
    over2years
    Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Alentis Therapeutics AG | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ALE.C04
    over2years
    FEGATO-01: A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis (clinicaltrials.gov)
    P1b, N=28, Recruiting, Alentis Therapeutics AG | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    TIMP1 (Tissue inhibitor of metalloproteinases 1)
    over2years
    REscue of Nephrons With ALe.F02 (RENAL-F02) (clinicaltrials.gov)
    P2, N=60, Recruiting, Alentis Therapeutics AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab)
    over2years
    Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Alentis Therapeutics AG
    New P1/2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ALE.C04